id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2023-D-4177-0021,FDA,FDA-2023-D-4177,Quality Considerations for Topical Ophthalmic Drug Products; Revised Draft Guidance for Industry; Availability,Notice,Notice of Availability,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T15:10:09Z,2023-28595,0,0,090000648636165b
FDA-2023-D-4177-0022,FDA,FDA-2023-D-4177,Quality Considerations for Topical Ophthalmic Drug Products; Guidance for Industry; Draft Guidance,Other,Guidance,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,2024-02-27T04:59:59Z,2025-02-04T02:01:06Z,,1,0,09000064863613f7
FDA-2023-D-4177-0001,FDA,FDA-2023-D-4177,Quality Considerations for Topical Ophthalmic Drug Products; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2023-10-13T04:00:00Z,2023,10,2023-10-13T04:00:00Z,,2023-10-13T13:56:46Z,2023-22650,0,0,09000064860cde7d
FDA-2023-D-4177-0002,FDA,FDA-2023-D-4177,Quality Considerations for Topical Ophthalmic Drug Products Guidance for Industry DRAFT GUIDANCE,Other,Guidance,2023-10-13T04:00:00Z,2023,10,2023-10-13T04:00:00Z,2023-12-13T04:59:59Z,2023-12-28T15:50:15Z,,0,0,09000064860cdf75